And the number of ctDNAs found in the blood increases with the progression of the disease.503 Moreover, it has been demonstrated that arch-related mutations (DNMT3A and TET2 genes) may be associated with poor prognosis in endometrial cancer patients, and DNMT3A mutations are more likely to be detected in EC patients in particular.504 The simple method of extraction and the ability to store for a long time prior to analysis make the detection of ctDNAs expected to be a potential marker for the diagnosis of EC. The gene discussed is DNMT3A; the disease is endometrial cancer.